An oral pill beat placebo at stopping hereditary angioedema attacks

Hereditary angioedema is a rare inherited disorder in which attacks of swelling — in the face, limbs, gut, or airway — strike without warning and, untreated, can last for days. The swelling is driven by bradykinin, a signalling molecule that makes blood vessels leak [s1]. On-demand treatments exist, but the fastest-acting ones are injected or infused, and an attack rarely waits for convenient timing. A new phase 3 trial tested whether a pill could do the job [s1].

What the trial tested

The drug is deucrictibant, described by its investigators as the first orally administered bradykinin B2 receptor antagonist — it blocks the receptor that bradykinin acts on, rather than the enzymes upstream that most other agents target [s1]. The trial, called RAPIDe-3, ran at 59 sites across 24 countries on six continents and enrolled adolescents aged 12 to under 18 and adults aged 18 to 75 with hereditary angioedema, including people whose C1-inhibitor levels are normal but who carry a documented causative genetic variant [s1]. All had experienced at least two attacks in the three months before screening and were already used to treating attacks with conventional on-demand therapy [s1].

The design is worth understanding, because it is unusual and it makes the result harder to fluke. This was a double-blind, 2×2 crossover trial [s1][s2]. Each participant was randomly assigned to treat two separate attacks — one with a 20 mg deucrictibant capsule and one with a matching placebo, in a randomly chosen order [s1]. Because every patient served as their own control, the comparison is between the same person's two attacks, which strips out much of the person-to-person variability that otherwise muddies a rare-disease study [s1]. The primary endpoint was the time to onset of symptom relief, defined by the patient rating their attack as at least "a little better" [s1].

The numbers

Between April 2024 and September 2025, 149 people were assessed and 134 were randomly assigned — 10 (7%) adolescents and 124 (93%) adults, with a median age of 38 years [s1]. In total, 113 participants treated 201 attacks, and the main efficacy analysis rested on the 88 participants who had a matched pair of treated attacks to compare [s1].

The gap between pill and placebo was wide. Onset of symptom relief came at a median of 1.28 hours with deucrictibant — the 95% confidence interval ran from 1.05 to 1.52 hours — against more than 12 hours with placebo, where the lower bound of the interval was 5.82 hours and the upper bound was literally off the scale at over 12 hours [s1]. The difference was highly statistically significant (p<0.0001) [s1]. In plain terms: on the active drug, most people felt their attack turning within about an hour and a quarter; on placebo, relief typically took the better part of a day or did not meaningfully arrive within the measurement window.

Safety looked clean over the short follow-up. Fatigue was the only adverse event reported more than once within three days of treatment — a single event in each of two participants, one of which was judged unrelated to the drug [s1]. No treatment-related adverse event was rated severe or serious, and none led anyone to stop treatment [s1].

How much weight it can bear

The result is genuinely strong on its own terms, but a few boundaries matter. The trial measured onset of relief, not complete resolution, and it followed each treated attack over a short window rather than tracking patients for months [s1]. A crossover design answers "does this work better than placebo for an attack?" cleanly; it is not built to compare deucrictibant head-to-head against the injected and infused on-demand treatments people already use, so the pill's place relative to existing options is not something this study settles. And with 134 participants, rare harms would not necessarily surface — the reassuring safety readout is real but short and small.

Two further caveats belong on the record. The trial was funded by Pharvaris, the company developing deucrictibant, and several investigators report financial ties to the firm and to competitors in the field [s1]. That does not invalidate a prespecified, placebo-controlled, blinded result, but it is the standard reason to want independent replication and longer safety data before the headline hardens.

What it means, and what to watch

For people with hereditary angioedema, the appeal of an effective oral on-demand option is obvious: a capsule that can be carried and swallowed at the first sign of an attack, without needles. This trial provides the first phase 3 evidence that such a pill can beat placebo on speed of relief, and do so with a tolerable short-term safety profile [s1]. It is not yet an approved product, and approval decisions rest with regulators weighing the full dossier.

The open questions are the practical ones: how deucrictibant compares with the fast injectable treatments, how consistently it resolves severe or airway attacks, and what long-term use shows. Until those are answered, the honest summary is the one the trial earned — against placebo, for speed of relief, it worked, and clearly [s1].

This article is informational and does not constitute medical advice.